中国医药
中國醫藥
중국의약
China Medicine
2015年
9期
1315-1318
,共4页
糖尿病神经病变%甲钴胺%依帕司他%神经传导速度
糖尿病神經病變%甲鈷胺%依帕司他%神經傳導速度
당뇨병신경병변%갑고알%의파사타%신경전도속도
Diabetic neuropathies%Methylcobalamin%Epalrestat%Nerve conduction velocity
目的 观察依帕司他联合甲钴胺治疗糖尿病周围神经病变的临床疗效.方法 选择2013年7月至2014年7月北京市中西医结合医院内分泌科门诊糖尿病周围神经病变患者96例,完全随机分为观察组和对照组,每组各48例.对照组给予甲钴胺胶囊,观察组给予甲钴胺胶囊联合依帕司他胶囊口服,3次/d.疗程为12周.分别于治疗前后比较2组患者的神经传导速度、多伦多临床评分系统(TCSS)评分.结果 观察组总有效率高于对照组,差异有统计学意义[89.6％ (43/48)比64.6％ (31/48),P＜0.05].对照组正中神经运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)和腓总神经MNCV、SNCV治疗前后比较,差异无统计学意义(P＞0.05).观察组正中神经MNCV、SNCV和腓总神经MNCV、SNCV治疗前后比较,差异均有统计学意义[正中神经:(38±6)m/s比(55 ±6) m/s、(38 ±4) m/s比(48±5)m/s,腓总神经:(38 ±4) m/s比(47±4) m/s、(40±5) m/s比(46±6) m/s,P＜0.05].治疗后观察组正中神经MNCV、SNCV和腓总神经MNCV高于对照组,差异有统计学意义[正中神经:(55 ±6) m/s比(42±9) m/s、(48±5) m/s比(40±4) m/s,腓总神经:(47±4) m/s比(40±5) m/s、(46±6) m/s比(40±6) m/s,P＜0.05].治疗后观察组TCSS评分低于对照组,差异有统计学意义[(9.8±3.5)分比(11.3±2.4)分,P＜0.05],治疗后观察组TCSS评分低于治疗前,差异有统计学意义[(9.8±3.5)分比(13.4±3.9)分,P＜0.05].结论 依帕司他联合甲钴胺治疗能明显改善糖尿病周围神经病变患者的临床症状和体征,疗效明显优于单用甲钴胺.
目的 觀察依帕司他聯閤甲鈷胺治療糖尿病週圍神經病變的臨床療效.方法 選擇2013年7月至2014年7月北京市中西醫結閤醫院內分泌科門診糖尿病週圍神經病變患者96例,完全隨機分為觀察組和對照組,每組各48例.對照組給予甲鈷胺膠囊,觀察組給予甲鈷胺膠囊聯閤依帕司他膠囊口服,3次/d.療程為12週.分彆于治療前後比較2組患者的神經傳導速度、多倫多臨床評分繫統(TCSS)評分.結果 觀察組總有效率高于對照組,差異有統計學意義[89.6％ (43/48)比64.6％ (31/48),P＜0.05].對照組正中神經運動神經傳導速度(MNCV)、感覺神經傳導速度(SNCV)和腓總神經MNCV、SNCV治療前後比較,差異無統計學意義(P＞0.05).觀察組正中神經MNCV、SNCV和腓總神經MNCV、SNCV治療前後比較,差異均有統計學意義[正中神經:(38±6)m/s比(55 ±6) m/s、(38 ±4) m/s比(48±5)m/s,腓總神經:(38 ±4) m/s比(47±4) m/s、(40±5) m/s比(46±6) m/s,P＜0.05].治療後觀察組正中神經MNCV、SNCV和腓總神經MNCV高于對照組,差異有統計學意義[正中神經:(55 ±6) m/s比(42±9) m/s、(48±5) m/s比(40±4) m/s,腓總神經:(47±4) m/s比(40±5) m/s、(46±6) m/s比(40±6) m/s,P＜0.05].治療後觀察組TCSS評分低于對照組,差異有統計學意義[(9.8±3.5)分比(11.3±2.4)分,P＜0.05],治療後觀察組TCSS評分低于治療前,差異有統計學意義[(9.8±3.5)分比(13.4±3.9)分,P＜0.05].結論 依帕司他聯閤甲鈷胺治療能明顯改善糖尿病週圍神經病變患者的臨床癥狀和體徵,療效明顯優于單用甲鈷胺.
목적 관찰의파사타연합갑고알치료당뇨병주위신경병변적림상료효.방법 선택2013년7월지2014년7월북경시중서의결합의원내분비과문진당뇨병주위신경병변환자96례,완전수궤분위관찰조화대조조,매조각48례.대조조급여갑고알효낭,관찰조급여갑고알효낭연합의파사타효낭구복,3차/d.료정위12주.분별우치료전후비교2조환자적신경전도속도、다륜다림상평분계통(TCSS)평분.결과 관찰조총유효솔고우대조조,차이유통계학의의[89.6％ (43/48)비64.6％ (31/48),P＜0.05].대조조정중신경운동신경전도속도(MNCV)、감각신경전도속도(SNCV)화비총신경MNCV、SNCV치료전후비교,차이무통계학의의(P＞0.05).관찰조정중신경MNCV、SNCV화비총신경MNCV、SNCV치료전후비교,차이균유통계학의의[정중신경:(38±6)m/s비(55 ±6) m/s、(38 ±4) m/s비(48±5)m/s,비총신경:(38 ±4) m/s비(47±4) m/s、(40±5) m/s비(46±6) m/s,P＜0.05].치료후관찰조정중신경MNCV、SNCV화비총신경MNCV고우대조조,차이유통계학의의[정중신경:(55 ±6) m/s비(42±9) m/s、(48±5) m/s비(40±4) m/s,비총신경:(47±4) m/s비(40±5) m/s、(46±6) m/s비(40±6) m/s,P＜0.05].치료후관찰조TCSS평분저우대조조,차이유통계학의의[(9.8±3.5)분비(11.3±2.4)분,P＜0.05],치료후관찰조TCSS평분저우치료전,차이유통계학의의[(9.8±3.5)분비(13.4±3.9)분,P＜0.05].결론 의파사타연합갑고알치료능명현개선당뇨병주위신경병변환자적림상증상화체정,료효명현우우단용갑고알.
Objective To investigate the effect of epalrestat combined with mecobalamin in treating diabetic peripheralneuropathy (DPN).Methods Totally 96 patients with DPN from July 2013 to July 2014 were randomly divided into control group (48 cases) which was orally administrated with mecobalamin (3 times/d for 12 weeks) and treatment group (48 cases) which was orally administrated with mecobalamin combined with epalrestat (3 times/d for 12 weeks).The nerve conduction velocity and toronto clinical scoring system (TCSS) scores were compared between the two groups before and after treatment.Results The total effective rate in treatment group was significantly higher than that in control group [89.6％ (43/48) vs 64.6％ (31/48),P ＜ 0.05].After treatment,the motor nerve conduction velocity (MNCV),sensory nerve conduction velocity (SNCV) median nerve and peroneal nerve in control group had no significantly changes (P ＞ 0.05) ; they were significantly increased in treatment group [median nerve MNCV:(55 ± 6) m/s vs (38 ± 6) m/s,median nerve SNCV:(48 ± 5) m/s vs (38 ±4) m/s; peroneal nerve MNCV:(47 ±4) m/s vs (38 ±4) m/s,peroneal nerve SNCV:(46 ± 6) m/s vs (40 ±5) m/s] (P ＜0.05).After treatment,the MNCV,SNCV of median nerve and peroneal nerve in treatment group were significantly higher than those in control group [median nerve MNCV:(55 ± 6) m/s vs (42 ±9) m/s,median nerve SNCV:(48 ±5) m/s vs (40 ±4) m/s; peroneal nerve MNCV:(47 ±4) m/s vs (40 ±5) m/s,peroneal nerve SNCV:(46 ±6) m/s vs (40 ±6) m/s] (P ＜0.05).After treatment,the TCSS score of treatment group was significantly reduced compared with that before treatment [(9.8 ± 3.5) scores vs (13.4 ± 3.9) scores] ; it was also significantly lower than that of control group [(9.8 ± 3.5) scores vs (11.3 ± 2.4) scores] (P ＜ 0.05).Conclusion Epalrestat combined with methylcobalamin in treating DPN can improve symptoms and nerve conduction velocity compared with single methylcobalamin.
